Mergers and acquisitions09 Oct 2025
Akero Therapeutics, a clinical-stage company focused on metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for...
Mergers and acquisitions07 Oct 2025
MaxCyte and Moonlight Bio have entered into a Strategic Platform License agreement. Moonlight Bio will utilize MaxCyte’s Flow Electroporation® technol...
Mergers and acquisitions02 Oct 2025
Elutia Inc. has finalized the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88...
Mergers and acquisitions18 Sept 2025
Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company, for up to $3.5 billion. The a...
Mergers and acquisitions09 Sept 2025
Novartis announced its acquisition of Tourmaline Bio, a clinical-stage biopharmaceutical company, for approximately $1.4 billion. The acquisition cen...
Mergers and acquisitions05 Sept 2025
Zydus Lifesciences and Synthon BV have entered into an exclusive licensing and supply agreement for Ozanimod Capsules, a generic version of ZEPOSIA®, ...
Mergers and acquisitions02 Sept 2025
Polpharma Biologics and MS Pharma have signed licensing agreements for the commercialization of three biosimilar candidates: vedolizumab (PB016), ocre...
Mergers and acquisitions02 Sept 2025
Servier and IDEAYA Biosciences announced an exclusive license agreement for darovasertib, a PKC inhibitor, for uveal melanoma treatment outside the US...
Mergers and acquisitions29 Aug 2025
LakeShore Biopharma Co., Ltd. announced the receipt of a revised preliminary non-binding proposal from a consortium (Oceanpine Capital and Crystal Pea...
Mergers and acquisitions26 Aug 2025
AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, a novel Phase 2 psychedelic compound for treating moderate-to-severe majo...
Mergers and acquisitions20 Aug 2025
AbbVie has completed its acquisition of Capstan Therapeutics, gaining access to CPTX2309, a first-in-class in vivo targeted lipid nanoparticle (tLNP) ...
Mergers and acquisitions14 Aug 2025
AleraCare, a provider of infusion and specialty pharmacy services, and PURE Healthcare, a medical group specializing in treating chronic conditions, a...
Mergers and acquisitions07 Aug 2025
CorMedix Inc. announced a definitive agreement to acquire Melinta Therapeutics LLC for $300 million. This acquisition significantly expands CorMedix's...
Mergers and acquisitions07 Aug 2025
Melinta Therapeutics, a commercial-stage biopharmaceutical company focused on acute and life-threatening illnesses, has been acquired by CorMedix Inc....
Mergers and acquisitions04 Aug 2025
Demetra, a medical company specializing in bone cements and biomaterials, announced the acquisition of OrthoFundamentals, a provider of single-use sol...
Mergers and acquisitions04 Aug 2025
Mallinckrodt plc and Endo, Inc. have completed their merger, forming a global leader in diversified therapeutics. The combined company boasts a broad ...
Mergers and acquisitions04 Aug 2025
Arrowhead Pharmaceuticals announced that its subsidiary, Visirna Therapeutics, has sold the rights to its investigational drug, plozasiran, for the tr...
Mergers and acquisitions28 Jul 2025
Adaptimmune Therapeutics plc announced the sale of its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million in cas...
Mergers and acquisitions28 Jul 2025
Hengrui Pharma and GSK have entered into agreements to co-develop up to 12 innovative medicines across respiratory, immunology & inflammation, and onc...
Mergers and acquisitions25 Jul 2025
Gate Bioscience, a biotechnology company focused on molecular gate technology, announced a collaboration and license agreement with Eli Lilly and Comp...
Mergers and acquisitions17 Jul 2025
Thermo Fisher Scientific announced an expansion of its strategic partnership with Sanofi. Thermo Fisher will acquire Sanofi's sterile manufacturing s...
Mergers and acquisitions16 Jul 2025
Repare Therapeutics has entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class PKMYT1 inhibitor. D...
Mergers and acquisitions15 Jul 2025
Cantargia AB has announced an agreement with Otsuka Pharmaceutical for the acquisition of Cantargia's CAN10 program. Otsuka will acquire all assets r...
Mergers and acquisitions10 Jul 2025
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding (MoU) to collaborate on the industrialization and scal...
Mergers and acquisitions09 Jul 2025
Merck has agreed to acquire Verona Pharma for approximately $10 billion. This acquisition brings Ohtuvayre (ensifentrine), a first-in-class COPD main...
Mergers and acquisitions08 Jul 2025
Chugai Pharmaceutical and Gero PTE. LTD. have entered a joint research and license agreement to develop novel antibody therapies for age-related disea...
Mergers and acquisitions03 Jul 2025
Ligand Pharmaceuticals announced the completion of its merger with Channel Therapeutics, forming Pelthos Therapeutics. Pelthos will launch ZELSUVMI™ ...
Mergers and acquisitions02 Jul 2025
EnChannel Medical announced the acquisition of Acutus Medical's AcQMap™ High Resolution Imaging and Mapping platform assets. This acquisition strength...
Mergers and acquisitions01 Jul 2025
Biofrontera Inc. announced the acquisition of all US assets related to Ameluz® and RhodoLED®, including the NDA and associated patents, from Biofronte...
Mergers and acquisitions30 Jun 2025
23andMe, a genetics-led consumer healthcare company, has received court approval for the sale of substantially all of its assets to TTAM Research Inst...
Mergers and acquisitions23 Jun 2025
Fujirebio Diagnostics, a subsidiary of Fujirebio Holdings, Inc., has acquired Plasma Services Group, Inc., a provider of high-quality biological mater...
Mergers and acquisitions19 Jun 2025
RyboDyn, a biotechnology company developing first-in-class immunotherapies targeting the 'dark proteome' (previously uncharacterized proteins), has be...
Mergers and acquisitions16 Jun 2025
Pierre Fabre Laboratories announced the acquisition of worldwide rights for PFL-721 and PFL-241, mutant-specific EGFR inhibitors, from Antares Therape...
Mergers and acquisitions13 Jun 2025
Medtronic plc announced that its planned new diabetes company, resulting from an intended separation, will be named MiniMed. This name honors the com...
Mergers and acquisitions12 Jun 2025
BioNTech, a global immunotherapy company, announced its intent to acquire CureVac, a clinical-stage biotech company focused on mRNA-based therapies, i...
Mergers and acquisitions10 Jun 2025
Quell Therapeutics announced that AstraZeneca has exercised its option to license a lead Treg cell therapy candidate from their joint Inflammatory Bow...
Mergers and acquisitions22 May 2025
Sanofi announced its acquisition of Vigil Neuroscience, a clinical-stage biotechnology company focused on neurodegenerative diseases. This acquisitio...
Mergers and acquisitions20 May 2025
CRISPR Therapeutics and Sirius Therapeutics announced a multi-target collaboration to co-develop and co-commercialize SRSD107, a long-acting siRNA the...
Merger and Acquisitions06 May 2025
bluebird bio, Inc. announced that it has received all necessary regulatory approvals for its acquisition by Carlyle and SK Capital. The merger is exp...
Merger And Acquisitions02 May 2025
Repare Therapeutics announced it out-licensed its discovery platforms, including the SNIPRx platform and related intellectual property, to DCx Biother...
